blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2133340

EP2133340 - Novel benzazepine derivatives [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.11.2013
Database last updated on 03.09.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Glaxo Group Limited
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[2013/18]
Former [2009/51]For all designated states
Glaxo Group Limited
Glaxo Wellcome House Berkeley Avenue
Greenford, Middlesex UB6 0NN / GB
Inventor(s)01 / Sehmi, Sanjeet Singh
GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow, Essex CM19 5AW / GB
02 / Wilson, David Matthew
GlaxoSmithKline
Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY / GB
03 / Witherington, Jason
GlaxoSmithKline
Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY / GB
04 / Bamford, Mark James
GlaxoSmithKline
Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY / GB
05 / Dean, David Kenneth
GlaxoSmithKline
New Frontiers Science Park South
Harlow, Essex CM19 5AW / GB
 [2013/03]
Former [2009/51]01 / Sehmi, Sanjeet Singh
GlaxoSmithKline New Frontiers Science Park South Third Avenue
Harlow, Essex CM19 5AW / GB
02 / Wilson, David Matthew
GlaxoSmithKline Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY / GB
03 / Witherington, Jason
GlaxoSmithKline Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY / GB
04 / Bamford, Mark James
GlaxoSmithKline Gunnels Wood Road
Stevenage, Hertfordshire SG1 2NY / GB
05 / Dean, David Kenneth
GlaxoSmithKline New Frontiers Science Park South
Harlow, Essex CM19 5AW / GB
Representative(s)Hillier, Mark, et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[2012/34]
Former [2009/51]Breen, Anthony Paul, et al
GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Application number, filing date09168438.118.12.2003
[2009/51]
Priority number, dateGB2002002982020.12.2002         Original published format: GB 0229820
GB2003001260702.06.2003         Original published format: GB 0312607
[2009/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2133340
Date:16.12.2009
Language:EN
[2009/51]
Type: B1 Patent specification 
No.:EP2133340
Date:16.01.2013
Language:EN
[2013/03]
Search report(s)(Supplementary) European search report - dispatched on:EP13.11.2009
ClassificationIPC:C07D223/16, A61K31/55, A61P25/00
[2009/51]
CPC:
C07D223/16 (EP,KR,US); A61K31/55 (KR); A61P1/04 (EP);
A61P11/00 (EP); A61P11/02 (EP); A61P11/06 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP);
A61P25/06 (EP); A61P25/08 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P3/04 (EP);
A61P43/00 (EP); A61P7/00 (EP); A61P9/00 (EP);
C07D401/12 (EP,KR,US); C07D401/14 (EP,KR,US); C07D403/12 (EP,US);
C07D403/14 (EP,US); C07D405/14 (EP,US); C07D409/12 (EP,US);
C07D409/14 (EP,US); C07D413/14 (EP,US); C07D417/12 (EP,US);
C07D417/14 (EP,US); C07D471/04 (EP,US); C07D491/04 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2009/51]
Extension statesLT14.05.2010
LV14.05.2010
TitleGerman:Neuartige Benzazepin-Derivate[2009/51]
English:Novel benzazepine derivatives[2009/51]
French:Nouveaux dérivés de benzazépine[2009/51]
Examination procedure21.08.2009Examination requested  [2009/51]
20.07.2010Despatch of a communication from the examining division (Time limit: M06)
28.01.2011Reply to a communication from the examining division
24.07.2012Communication of intention to grant the patent
13.11.2012Fee for grant paid
13.11.2012Fee for publishing/printing paid
Parent application(s)   TooltipEP03785885.9  / EP1572215
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030785885) is  15.10.2007
Opposition(s)17.10.2013No opposition filed within time limit [2013/52]
Fees paidRenewal fee
21.08.2009Renewal fee patent year 03
21.08.2009Renewal fee patent year 04
21.08.2009Renewal fee patent year 05
21.08.2009Renewal fee patent year 06
22.10.2009Renewal fee patent year 07
22.11.2010Renewal fee patent year 08
07.12.2011Renewal fee patent year 09
07.12.2012Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.12.2003
AT16.01.2013
CY16.01.2013
CZ16.01.2013
DK16.01.2013
EE16.01.2013
FI16.01.2013
MC16.01.2013
NL16.01.2013
RO16.01.2013
SE16.01.2013
SI16.01.2013
SK16.01.2013
TR16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
[2015/34]
Former [2015/32]AT16.01.2013
CY16.01.2013
CZ16.01.2013
DK16.01.2013
EE16.01.2013
FI16.01.2013
MC16.01.2013
NL16.01.2013
RO16.01.2013
SE16.01.2013
SI16.01.2013
SK16.01.2013
TR16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
Former [2014/33]AT16.01.2013
CY16.01.2013
CZ16.01.2013
DK16.01.2013
EE16.01.2013
FI16.01.2013
MC16.01.2013
NL16.01.2013
RO16.01.2013
SE16.01.2013
SI16.01.2013
SK16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
Former [2013/52]AT16.01.2013
CY16.01.2013
CZ16.01.2013
DK16.01.2013
EE16.01.2013
FI16.01.2013
NL16.01.2013
RO16.01.2013
SE16.01.2013
SI16.01.2013
SK16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
Former [2013/49]AT16.01.2013
CZ16.01.2013
DK16.01.2013
EE16.01.2013
FI16.01.2013
NL16.01.2013
RO16.01.2013
SE16.01.2013
SI16.01.2013
SK16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
Former [2013/48]AT16.01.2013
DK16.01.2013
EE16.01.2013
FI16.01.2013
NL16.01.2013
SE16.01.2013
SI16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
Former [2013/40]AT16.01.2013
FI16.01.2013
NL16.01.2013
SE16.01.2013
SI16.01.2013
BG16.04.2013
GR17.04.2013
PT16.05.2013
Former [2013/37]AT16.01.2013
FI16.01.2013
NL16.01.2013
SE16.01.2013
SI16.01.2013
BG16.04.2013
GR17.04.2013
Former [2013/36]AT16.01.2013
SE16.01.2013
BG16.04.2013
Former [2013/34]SE16.01.2013
BG16.04.2013
Documents cited:Search[A]WO0006254  (BIOPROJET SOC CIV [FR], et al) [A] 1-22 * example - *;
 [A]WO0187834  (TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al) [A] 1-22 * example - *;
 [PA]EP1283199  (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [PA] 1-22* example - *
by applicantGB1268243
 DE2207430
 FR2171879
 US4210749
 US5364791
 US5874534
 US5935934
 WO9955677
 WO0021951
 WO0023437
 WO0103680
 JP2001226269
 WO0187834
 WO0202530
 WO0214513
 WO0215934
 WO0240471
 WO02062423
    - LEURS, TRENDS PHARMACOL. SCI., (1998), vol. 19, pages 177 - 183
    - SCHLICKER ET AL., FUNDAM. CLIN. PHARMACOL., (1994), vol. 8, pages 128 - 137
    - ONODERA ET AL., The Histamine H3 receptor, ELSEVIER SCIENCE B.V., (1998), pages 255 - 267
    - GIOVANNI ET AL., BEHAV. BRAIN RES., (1999), vol. 104, pages 147 - 155
    - BIOORG.MED.CHEM.LETT., (2000), vol. 10, no. 22, pages 2553 - 2556
    - KENJI NIIYAMA ET AL., BIOORG. MED. CHEM LETT., (2002), vol. 12, no. 21, pages 3041 - 3054
    - TETRAHEDRON, (2000), vol. 56, no. 39, pages 7705 - 7713
    - EVANS, BRIAN J.; TAKAHASHI DOI, JOYCE; MUSKER, W. KENNETH, J.ORG.CHEM., (1990), vol. 55, no. 9, pages 2580 - 2586
    - A.E MOURAD ET AL., J. HET. CHEM, (1992), vol. 29, no. 6, pages 1583 - 1592
    - HUVAR, A. ET AL., MOL. PHARMACOL., (1999), vol. 55, no. 6, pages 1101 - 1107
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.